Feedback from Qiagen IR Regarding Thermo Fisher Deal
Summary: We had a discussion with various people to get an update on Qiagen as well as get some further clarification in relation to its deal with...
531 Views
Thermofisher Bids for Qiagen - A COVID-19 Pivot?
Summary: QIAGEN NV (QIA GY)Ā , a German life sciences company focused recently on COVID-19 molecular test kits and assay technologies for molecular...
575 Views
Wuxi Apptec čÆęåŗ·å¾· IPO: Welcome to the A/H Universe
WuXi Apptec is set to be the newest A/H pair with its upcoming HK listing that is set to raise USD 1 billion. The A-share (603289 CH) recorded 15...
1k Views
WuXi Biologics IPO Review - An Opportunity to Get Exposure to Biologics in China
WuXi Biologics (2269 HK) is looking to raise US$461-511m through the issuance of primary (88%) and secondary (12%) shares. Ā Proceeds will be used...
1k Views
WuXi Biologics: Pass on This Valuation
The company's underwriters have announced a price range of HK$18.60 - HK$20.60 which implies a marketĀ cap of US$2.7-3.0 billion. We recommend...
987 Views